Patients manifesting with both HIV and cancer face a complex therapeutic challenge. The interplay between these two diseases can lead to unique medical manifestations and present significant obstacles in achieving optimal success. Pharmacological combinations offer a promising avenue for improving the management of this vulnerable patient segment.